Sign In
Buy NERV
$4.68
-0.0700 (-1.47%)
At Close: Jun 03, 2026
Theravance Biopharma (TBPH) Receives a Buy from H.C. Wainwright
03:26pm, Thursday, 23'rd Apr 2020
In a report released today,
Douglas Tsao
from H.C. Wainwright maintained a
Buy
rating on Theravance Biopharma (
TBPH
–
Research Report
), with a price target of
$32.00
. The company’s shares close
Minerva Neurosciences, Inc. (NASDAQ:NERV): What Does Its Beta Value Mean For Your Portfolio?
05:40pm, Monday, 20'th Apr 2020
If you own shares in Minerva Neurosciences, Inc. (NASDAQ:NERV) then it's worth thinking about how it contributes to...
Evolus (EOLS) Gets a Buy Rating from H.C. Wainwright
11:08am, Monday, 20'th Apr 2020
H.C. Wainwright analyst Douglas Tsao reiterated a Buy rating on Evolus (EOLS) today and set a price target of $16.00. The company's shares closed last
Evolus (EOLS) Gets a Buy Rating from H.C. Wainwright
11:08am, Monday, 20'th Apr 2020
H.C. Wainwright analyst
Douglas Tsao
reiterated a
Buy
rating on Evolus (
EOLS
–
Research Report
) today and set a price target of
$16.00
. The company’s shares closed last Friday at $4.43, close t
Analysts Offer Insights on Healthcare Companies: Bicycle Therapeutics (BCYC) and Amag Pharmaceuticals (AMAG)
11:16am, Friday, 17'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Bicycle Therapeutics (BCYC) and Amag Pharmaceuticals (AMAG)
Wall Street Analysts Are Bullish on Top Healthcare Picks
11:18am, Tuesday, 14'th Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Coherus Biosciences (CHRS), Arcturus Therapeutics (ARCT)
SAGE Therapeutics (SAGE) Receives a Hold from H.C. Wainwright
06:00am, Sunday, 12'th Apr 2020
In a report issued on April 8, Douglas Tsao from H.C. Wainwright reiterated a Hold rating on SAGE Therapeutics (SAGE
At a CAGR of 5.2%, Bipolar Disorder Treatment Market to Surpass US$ 10,925.5 Million globally by end of 2027, Says CMI
02:16pm, Friday, 10'th Apr 2020
SEATTLE, April 10, 2020 -- According to Coherent Market Insights, the global bipolar disorder treatment market is estimated to be valued at US$ 7,288.3 million in 2019 and is.
Theravance Biopharma (TBPH) Receives a Buy from H.C. Wainwright
03:55pm, Thursday, 09'th Apr 2020
H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Theravance Biopharma (TBPH) today and set a price target of $32.00. The company's shares
Theravance Biopharma (TBPH) Receives a Buy from H.C. Wainwright
03:55pm, Thursday, 09'th Apr 2020
H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on Theravance Biopharma (TBPH – Research Report) today and set a
H.C. Wainwright Thinks Crinetics Pharmaceuticals’ Stock is Going to Recover
06:21am, Wednesday, 08'th Apr 2020
In a report released yesterday, Douglas Tsao from H.C. Wainwright reiterated a Buy rating on Crinetics Pharmaceuticals (CRNX – Research
Backtesting The Pullback Strategy On SPY
07:57pm, Tuesday, 07'th Apr 2020
The COVID-19 stock market decline entices traders to bet on the S&P 500 index to benefit from an upcoming recovery. The S&P 500 index has known multiple pullbac
Analysts' Top Healthcare Picks: Seattle Genetics (SGEN), Minerva Neurosciences (NERV)
03:41pm, Friday, 03'rd Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Seattle Genetics (SGEN), Minerva Neurosciences (NERV) and
Analysts’ Top Healthcare Picks: Seattle Genetics (SGEN), Minerva Neurosciences (NERV)
03:41pm, Friday, 03'rd Apr 2020
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Seattle Genetics (
SGEN
–
Research Report
), Minerva Neurosciences (
NERV
–
Research Report
) and O
Analysts Offer Insights on Healthcare Companies: Dynavax (DVAX), Crinetics Pharmaceuticals (CRNX) and Collplant Holdings (CLGN)
11:11am, Friday, 03'rd Apr 2020
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Dynavax (DVAX), Crinetics Pharmaceuticals (CRNX) and
